Open Access
- 14 January 2025
- journal article
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Abstract
Donor-derived cellular therapies play a pivotal role in optimizing outcomes after allogeneic hematopoietic stem-cell transplantation (HCT). This article reviews three key post-transplant interventions: donor lymphocyte infusion (DLI), hematopoietic stem-cell boost, and mesenchymal stromal cell (MSC) infusion. DLI remains a cornerstone strategy for enhancing graft-versus-leukemia effects, preventing or treating relapse, and promoting immune reconstitution, while also carrying risk of graft-versus-host disease. Stem-cell boosts, typically performed using CD34⁺ selected products, offer an effective approach for managing poor graft function or mixed chimerism without significantly increasing alloimmune toxicity. MSC infusion has emerged as a promising immunomodulatory therapy for steroidrefractory graft-versus-host disease and for facilitating engraftment, owing to its anti-inflammatory and tissueregenerative properties.Keywords
This publication has 42 references indexed in Scilit:
- The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host diseaseAnnals of Hematology, 2023
- CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of LiteratureClinical Hematology International, 2023
- Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2021
- Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantationImmuno-Oncology and Technology, 2020
- A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2020
- Post-Transplant CD34+ Selected Stem Cell “Boost” for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune DeficienciesTransplantation and Cellular Therapy, 2018
- Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2017
- Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte InfusionsTransplantation and Cellular Therapy, 2016
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2009